As between the sponsoring organisations, the results of the study will be the sole and exclusive property of Oxford University. Oxford will initiate and control the filing of any patent applications. Oxford has granted NFCR an exclusive first option to negotiate in good faith a royalty-bearing licence over the results for further drug development. Any royalties NFCR receives from any licensing will be granted back to Oxford University as research funding. Oxford reserves a royalty-free, non-exclusive licence to use the intellectual property internally, in connection with Oxford’s teaching, research and public service mission.
Yes. Prof. Graham Richards' research group in the Chemistry Department of Oxford, the project coordinators, will publish the results. This group originally designed the project and is currently orchestrating the study. Scientific interpretation of the results from this study will take some time. Results and scientific findings will be published in the usual manner through a peer-reviewed process.
The United States Department of Defense (USAMRIID). Only US government supported research sites could test the drug as research restrictions control work on the vaccinia virus.